Bellicum Pharmaceuticals, Inc. (BLCM) Receives Buy Rating from Jefferies Group LLC
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued on Thursday. They currently have a $16.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $18.00. Jefferies Group LLC’s price objective indicates a potential upside of 89.69% from the stock’s previous close.
Several other research analysts have also recently weighed in on BLCM. Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. BidaskClub cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. Finally, Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Bellicum Pharmaceuticals has a consensus rating of “Buy” and an average target price of $26.20.
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 8.435 on Thursday. The company’s market capitalization is $279.22 million. The company’s 50 day moving average price is $11.69 and its 200-day moving average price is $12.39. Bellicum Pharmaceuticals has a 52 week low of $8.10 and a 52 week high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 71.51% and a negative net margin of 17,957.31%. During the same period in the previous year, the firm earned ($0.61) earnings per share. Equities research analysts expect that Bellicum Pharmaceuticals will post ($2.84) earnings per share for the current year.
In related news, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total transaction of $77,246.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,571 shares of company stock valued at $367,295. 23.30% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the stock. Foresite Capital Management III LLC acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth approximately $11,328,000. LMR Partners LLP acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth approximately $3,339,000. JPMorgan Chase & Co. boosted its stake in Bellicum Pharmaceuticals by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock worth $28,811,000 after buying an additional 227,668 shares during the period. Sphera Funds Management LTD. acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth approximately $2,468,000. Finally, Vanguard Group Inc. boosted its stake in Bellicum Pharmaceuticals by 17.8% in the first quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock worth $13,100,000 after buying an additional 160,151 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.